Abstract
In this issue of Blood, Molle et al demonstrate that on-target effects of ruxolitinib, a JAK1/2 inhibitor, reduce JAK2-mediated phosphorylation of STA......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
